Navigation Links
MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium
Date:12/7/2011

FRAMINGHAM, Mass., Dec. 7, 2011 /PRNewswire/ -- Data from the MarginProbe pivotal study were presented today during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.  The results were presented by Dr. Freya Schnabel, Director of Breast Surgery, NYU Langone Medical Center, New York University, New York, New York.  In a 596 patient randomized study, adjunctive use of MarginProbe significantly improved surgical outcomes by improving surgeons' ability to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by 57%.

"Second surgeries are difficult on the patient, both physically and emotionally," said Dr. Schnabel.  "On average, about 30% of patients will require more than one surgery to completely remove the cancer.  In our study, we saw a similar rate in the control arm, but by using MarginProbe, we were able to cut that in half.  This represents a substantial improvement in patient care and quality, as well as reducing costs.  I am very excited to see the device available to surgeons in the US."

"We are very pleased with the response of the surgeon community to these data.  Every lumpectomy surgery has the need for improved ability to achieve cancer-free margins and we believe these data present substantial evidence supporting the approval and widespread adoption of the MarginProbe System," said Dan Levangie, CEO of Dune Medical Devices.

About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer.  The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.  The MarginProbe System is Dune's first commercial product and is commercially available in Europe.  The MarginProbe device is an investigational device in the U.S.

About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology.  Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. 

Dune Medical Devices is a privately held company financed by Apax Partners since 2004.  It has offices in the U.S., Israel, Germany and Switzerland.  For more information, please visit www.dunemedical.com   

Contact:
Michael Graffeo
Dune Medical Devices
Michael.graffeo@dunemedical.com
(508) 620-2782


'/>"/>
SOURCE Dune Medical Devices
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
2. Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
3. ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514
4. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
5. EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System
6. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
7. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
10. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
11. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
(Date:7/6/2017)... July 6, 2017 ThriveRx, the nutrition division of Diplomat Specialty ... to thrive on nutrition support. To celebrate its anniversary, ThriveRx ... has a fresh new look with improved organization to create the best ... ... "We,ve made ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... Dr. Jig Patel is ... Schaumburg, IL, with or without a referral. Understanding the difficulties that face people who ... when they choose this permanent alternative to removable dentures and bridges. Not only does ...
(Date:7/20/2017)... , ... July 19, 2017 , ... ... $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral dental ... health care needs in rural and underserved areas. , The Predoctoral Pediatric Training ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... may sometimes lead to, or worsen, varicose veins in some patients, according to ... while avoiding certain not-so-good practices, like excessive sitting or standing, or regularly nicking ...
(Date:7/18/2017)... Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place ... will be speaking on the therapeutic benefits of medical cannabis for both pediatric and ...
(Date:7/18/2017)... Calif. (PRWEB) , ... July 18, 2017 , ... The results of an international clinical ... a drug therapy for a severe type of muscular dystrophy holds promise for a subgroup ... , Craig McDonald and colleagues at 53 study sites in 18 countries describe ...
Breaking Medicine News(10 mins):